11.10.2020
|
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
|
11.05.2020
|
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
|
11.02.2020
|
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
|
9.03.2020
|
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
|
8.12.2020
|
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
|
8.05.2020
|
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
|
6.11.2020
|
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
5.27.2020
|
Viela Bio Announces Pricing of Public Offering of Common Stock
|
5.27.2020
|
Viela Bio Announces Pricing of Public Offering of Common Stock
|
5.26.2020
|
Viela Bio Announces Proposed Public Offering of Common Stock
|